mk0429
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2000 (NCT00533650)
Timeline
Indications
Mechanism of action
- Vitronectin receptor alphaINHIBITOR
ITGAV inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mk0429
- mk0429
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00302471 | Phase 1 | Mar 1, 2006 | Merck |
| NCT00533650 | Phase 2 | Dec 1, 2000 | Merck |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 2 | 2 | 2 | 2000 |
1 organizations
Page 1 / 1